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Prolonged exposure to glucocorticoids (GCs) causes various metabolic derangements. These in-
clude obesity and insulin resistance, as inhibiting glucose utilization in adipose tissues is a
major function of GCs. Although adipose tissue distribution and glucose homeostasis are sex-
dependently regulated, it has not been evaluated whether GCs affect glucose metabolism and
adipose tissue functions in a sex-dependent manner. In this study, high-dose corticosterone
(rodent GC) treatment in C57BL/6J mice resulted in nonfasting hyperglycemia in male mice only,
whereas both sexes displayed hyperinsulinemia with normal fasting glucose levels, indicative of
insulin resistance. Metabolic testing using stable isotope-labeled glucose techniques revealed a
sex-specific corticosterone-driven glucose intolerance. Corticosterone treatment increased adi-
pose tissue mass in both sexes, which was reflected by elevated serum leptin levels. However,
female mice showed more metabolically protective adaptations of adipose tissues than did male
mice, demonstrated by higher serum total and high-molecular-weight adiponectin levels, more
hyperplastic morphological changes, and a stronger increase in mRNA expression of adipogenic
differentiation markers. Subsequently, in vitro studies in 3T3-L1 (white) and T37i (brown) adi-
pocytes suggest that the increased leptin and adiponectin levels were mainly driven by the el-
evated insulin levels. In summary, this study demonstrates that GC-induced insulin resistance is
more severe inmalemice than in femalemice, which can be partially explained by a sex-dependent
adaptation of adipose tissues. (Endocrinology 160: 2367–2387, 2019)
Glucocorticoids (GCs) are steroid hormones producedby the adrenal gland. External stressors such
as infection, trauma, food deprivation, and physical
or psychological stress enhance the activity of the
hypothalamic-pituitary-adrenal (HPA) axis and trigger
the adrenal gland to secrete an endogenous GC: cortisol
for humans or corticosterone for rodents (1).
Exogenous synthetic GCs are widely prescribed for a
number of autoimmune diseases and allergic reactions
due to their immunosuppressive properties (2). However,
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fatty acid–free BSA; GC, glucocorticoid; GC-MS, gas chromatography–mass spectrom-
etry; GCR, glucose clearance rate; GR, GC receptor; gWAT, gonadal WAT; HOMA-IR,
homeostatic model assessment of insulin resistance; HMW, high-molecular-weight; HPA,
hypothalamic-pituitary-adrenal; IPGTT, IP glucose tolerance test; iWAT, inguinal WAT;
MR, mineralocorticoid receptor; NFBG, nonfasting blood glucose; PC, P value for
corticosterone treatment; PFA, paraformaldehyde; PI, P value for insulin treatment;
PPC, P value for pretreatment with corticosterone; PPI, P value for pretreatment with
insulin; PS, P value for sex; P/S, penicillin/streptomycin; PSI, P value for stimulatory insulin;
PT, P value for time (duration) of treatment; RT, room temperature; WAT, white adipose
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prolonged exposure to elevated endogenous GCs, such as
in Cushing syndrome, or to exogenous GCs leads to
various metabolic derangements, such as progressive
weight gain, truncal obesity due to expansion of the
visceral white adipose tissue (WAT), loss of subcutane-
ous WAT mass, and development of insulin resistance
that might result in diabetes mellitus (2–5). These effects
are largely attributable to the role of GC in the control
of glucose homeostasis, as they promote hepatic glu-
cose production (gluconeogenesis) and inhibit glucose
utilization in WAT and skeletal muscles (1, 4).
The HPA axis is controlled in a sexually dimorphic
manner: female rodents have higher basal and stress-
induced corticosterone levels with a less robust negative
feedback on the HPA axis than do males (6, 7). The fact
that the concentrations of corticosteroid-binding globulin,
the glycoprotein that binds 80% of circulating cortico-
sterone, are higher in females than in males likely con-
tributes to this sex difference (6, 8). Sex steroid hormones
are also involved in the sex-dependent control of the HPA
axis (6, 7). In adult male rats, castration and estradiol
treatment increase responsiveness of the HPA axis to
external stressors whereas ovariectomy and androgen
replacement in female rats decrease this response (7).
Intriguingly, adipose tissue distribution and function
show many sex-dependent characteristics as well. Con-
cerning WAT distribution, females have relatively more
subcutaneousWAT and less visceral WAT than do males
(9, 10). Females also have a relatively higher activity of
the metabolically active brown adipose tissue (BAT) and
have more brown-like adipocytes in their WAT depots
(11, 12). Furthermore, glucose metabolism has been
shown to differ between males and females, with female
mice being more insulin sensitive and glucose tolerant
than male mice (13).
Despite these sex differences in HPA axis regulation,
adipose tissue distribution, and glucose homeostasis,
high-dose GC- or stress-induced adverse effects have only
been studied in male rodents (14, 15). Whether the
metabolic consequences of exposure to high-dose GC
differ between males and females is still unknown. To
address this knowledge gap, we have studied the effects of
2-week high-dose corticosterone on whole-body glucose
metabolism and adipose tissue function in both male and
female C57BL/6J mice.
Materials and Methods
Animals, housing conditions, and
corticosterone treatment
Eight-week-old C57BL/6J mice (24 males and 24 females)
were obtained from Charles River Laboratories (Maastricht,
Netherlands). Upon arrival, mice were group housed (three
mice per cage) at room temperature (RT; ;22°C) on a 12-hour
light/12-hour dark cycle (lights on at 8:00 AM). Chow food
pellets [801722CRM (P), Special Diets Services, Essex, UK] and
water were available ad libitum. We provided tissue papers
(Tork extra soft facial tissue, SCA Hygiene Products, Zeist,
Netherlands) as nesting material and woodchips (Lignocel BK
8/15, J. Rettenmaier & So¨hne, Rosenberg, Germany) as bed-
ding material. All experimental procedures were approved by
the Animal Ethics Committee at Erasmus MC, Rotterdam,
Netherlands.
After 10 to 14 days of acclimatization, a corticosterone
pellet [50 mg of corticosterone (Sigma-Aldrich, Zwijndrecht,
Netherlands) and 50 mg of cholesterol] or a vehicle pellet
(100 mg of cholesterol) was implanted subcutaneously at the
dorsal region of the neck under isoflurane (Teva Pharmachemie,
Haarlem, Netherlands) anesthesia and carprofen (Rimadyl
Cattle, Pfizer Animal Health, Capelle aan den IJssel, Nether-
lands) analgesia. Subsequently, mice were single housed and
enrolled in experiment 1 or 2.
Experiment 1: nonfasting glucose monitoring and
endpoint blood and tissue collection
For experiment 1, mice were weighed on day 0 (before pellet
implantation) and on days 3, 5, 7, 10, and 12 after pellet
implantation at 1:00 PM. At the same time, their nonfasting
blood glucose (NFBG) level was determined by tail-tip bleeding
using a glucometer and test strips (FreeStyle Freedom Lite,
Abbott, Hoofddorp, Netherlands). On day 12, we weighed the
food pellets and transferred the mice to a new cage with similar
conditions. On day 14 at 8:00 AM, the mice and food pellets
were weighed again, the NFBG was measured, and the bedding
material was collected for further processing. Next, we trans-
ferred the mice to clean cages with similar conditions except for
the presence of food pellets. At 1:00 PM (after 5 hours of
fasting), the fasting blood glucose (FBG) level was determined
and the mice were euthanized by cardiac puncture under iso-
flurane anesthesia. Thymus involution was confirmed in the
corticosterone-treated mice. Blood was stored immediately at
4°C and various tissues (e.g., BAT, WAT, quadriceps femoris
muscle, and liver) were dissected, weighed, and snap-frozen in
liquid nitrogen or fixed in 4% paraformaldehyde (PFA) in PBS
at RT. The inguinal (also known as posterior subcutaneous)
WAT (iWAT) and gonadal WAT (gWAT) depots were cut in
half. One half of iWATwas snap-frozen; one half of gWATwas
further divided and snap-frozen or fixed as described above.
The other half of iWAT and gWAT was washed in PBS and
preincubated in DMEM/F12 medium (catalog no. 21331020,
Gibco, Life Technologies Europe, Bleiswijk, Netherlands) with
2% fatty acid–free BSA (FF-BSA; catalog no. 03117057001,
Roche Diagnostics, Mannheim, Germany) at RT for sub-
sequent ex vivo stimulation.
Serum (obtained after an overnight clotting at 4°C) and
snap-frozen tissues were stored at 280°C until analyses. After
24-hour fixation in PFA at RT, tissues were stored in 70%
ethanol until histological analysis. Feces were collected from the
bedding material, air-dried, weighed, crushed, and extracted
with ethanol for fecal corticosterone measurement, as described
previously (16).
Experiment 2: IP glucose tolerance test
For experiment 2, mice were weighed and their NFBG was
determined on days 0 (before pellet implantation), 7, and 14 at
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8:00 AM. Next, food pellets were removed and the mice were
fasted until 1:00 PM when their FBG was determined and one
blood spot (;6 mL) was collected on filter paper (TFN 180 g/m2,
Sartorius Stedim Biotech, Go¨ttingen, Germany) for fasting
blood insulin (FBI) measurement. Additionally, on day 14
mice were subjected to an IP glucose tolerance test (IPGTT).
For this, the mice received an IP injection of 2 g/kg glucose
[20% glucose solution, which contains 95% D-(1)-glucose
(Sigma-Aldrich) and 5% [U-13C6]-D-glucose (Cambridge
Isotope Laboratories, Andover, MA)]. Blood glucose levels
were determined and two blood spots (;3 mL for glucose ki-
netic analysis and ;6 mL for insulin measurement) were col-
lected on filter paper at 5, 15, 30, 45, 75, and 120 minutes after
glucose injection. After the experiment, mice were euthanized
by cervical dislocation under isoflurane anesthesia. Blood spots
were air-dried for 2 hours and stored at 220°C (for insulin
measurement) or at RT (for glucose extraction).
Insulin stimulation of WAT explants
Pieces of iWAT and gWAT preincubated with 2%FF-BSA in
DMEM/F12 (from experiment 1) were cut into small pieces of
;20 mg and incubated in DMEM/F12 medium containing 2%
FF-BSA (Roche Diagnostics) with or without 1 mM insulin
(Sigma-Aldrich) at 37°C in a humidified incubator with 5%
CO2 for 2 hours (refreshed once with fresh solution after 1 hour
of incubation). Subsequently, tissues were washed twice in cold
PBS and stored at 280°C until protein extraction.
Adipose tissue histology and adipocyte
size quantification
PFA-fixed gWAT, anterior subcutaneous (also known as
axillary) WAT (aWAT), and BAT were embedded in paraffin.
After manually sectioned with a microtome, 8-mm-thick WAT
and 5-mm-thick BAT sections were mounted on glass slides and
stained with hematoxylin and eosin.
Representative images from three random sections of gWAT
and aWAT from each animal were taken with a digital imaging
system (Nikon Eclipse E400 and Nikon Digital Sight DS-L1,
Nikon Corporation, Tokyo, Japan). To quantify adipocyte size,
we used an automated mode of Adiposoft, a plug-in of Fiji
(advanced distribution of ImageJ) software for accurately an-
alyzing number and size of adipocytes (17).
Circulating hormone and adipokine quantification
by ELISA
Serum and fecal concentrations of hormones and adipokines
of the mice from experiment 1 were determined according to the
manufacturers’ protocols. Serum total and high-molecular-
weight (HMW) adiponectin levels were measured with a
mouse HMW and total adiponectin ELISA kit (18). Serum
leptin was measured with a mouse/rat leptin ELISA kit (19).
Serum and fecal corticosterone levels were determined with a
corticosterone ELISA kit (20).
The insulin concentrations in the blood spots collected in
experiment 2 were determined as previously described (21)
using a rat insulin ELISA kit (22) with the Mouse Insulin
Standard (90020, Crystal Chem, Zaandam, Netherlands). In
brief, a completely filled blood spot on filter papers (6-mm
diameter) was punched out and eluted in guinea pig anti-
insulin in sample diluent overnight at 4°C, followed by the
standard procedure of the ELISA kit.
Derivatization and gas chromatography–mass
spectrometry measurements of glucose
Extraction of glucose from the filter paper blood spots, de-
rivatization of the extracted glucose, and gas chromatography–
mass spectrometry (GC-MS) measurements of the glucose
derivatives were done according to the analytical procedure
described before (23). In short, a disk was punched out of the
blood spots, glucose was extracted from the disk by incubating
it in ethanol/water (10:1 v/v), and glucose was derivatized to its
pentaacetate ester. Samples were analyzed by GC-MS (Agilent
5975C inert MSD, Agilent Technologies, Amstelveen, Neth-
erlands) with separation of derivatives on 30-m 3 0.25-mm
interior diameter (0.25-mm film thickness) capillary columns
(ZB-1701, Phenomenex, Utrecht, Netherlands) and with positive-
ion chemical ionization with methane. Measured by GC-MS,
the fractional isotopomer distribution (M0 toM6) was corrected
for the fractional distribution due to natural abundance of 13C
by multiple linear regression as described by Lee et al. (24) to
obtain the excess fractional distribution of mass isotopomers
(M0 to M6) due to the dilution of administered [U-13C6]-D-
glucose; that is, M6 represents the fractional contribution of the
administered tracer and was used in the calculations of blood
glucose kinetics.
Calculation of blood glucose metabolism
Tracer concentrations were calculated as the product of the
blood glucose concentration and the fractional contribution of
the tracer at that time point (t): [13C6-glucose]t5 (M6)t$[glucose]t.
To determine the effects of the IPGTT on glucose metab-
olism in mice, we used an adapted minimal model for glucose
metabolism after an oral glucose tolerance test (25). This
adapted model is presented in Fig. 1A and was used in SAAM II
software (version 2.3, The Epsilon Group, Charlottesville, VA).
To generate sufficient input data for this model, measured
data of blood glucose, blood insulin, and tracer concentra-
tions were fitted to the following formula to calculate the
concentration (C) of these metabolites at multiple time points
(t): Ct 5 Cb1Cð1Þ0$e2 kð1Þt 1 Cð2Þ0$e2kð2Þt 2 Cð3Þ0$e2 kð3Þt,
where b indicates the basal value and 0 indicates the estimated
value at time point 0. The bioavailability (F) of the bolus was
estimated from the tracer curve as follows:
F ¼ 1 2

Cð3Þ0kð1Þkð2Þ
Cð1Þ0kð2Þkð3Þ 1 Cð2Þ0kð1Þkð3Þ

:
The glucose kinetic parameters were calculated using the
compartmental model and the relevant equations (26–28), as
presented in Fig. 1. In this model, k1 and k2 are rate constants
for the glucose flux from the accessible plasma pool to the
inaccessible “tissue” pool and vice versa, whereas k3 is the rate
constant for the insulin flux from the accessible plasma pool to
the inaccessible tissue pool, and they are different from the rate
constants k(1), k(2), and k(3) used to describe the plasma glucose
vs time curve above. We adapted the volume of the accessible
glucose pool from literature; that is, 150 mL/kg was suggested
by Tissot et al. (29) and Gastaldelli et al. (30) for humans. The
insulin-independent glucose utilization was set to three times
the insulin-dependent glucose utilization under basal condi-
tions as was also used for humans (31, 32). Furthermore, under
basal conditions the independent utilization flux was esti-
mated at 45% of the endogenous glucose production (EGP). The
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fractional turnover rates (k0 through k4) were estimated within
the model.
In vitro adipocyte culture
The white preadipocyte cell line 3T3-L1 (33) and the
brown preadipocyte cell line T37i [(34); a gift provided by
Dr. M. Lombe`s, Inserm U1185, France] were used to study
direct effects of corticosterone and/or insulin on adipocytes.
3T3-L1 preadipocytes were cultured with basal medium
[3T3-BM:DMEM4.5 g/L glucose with L-glutamine and 25mM
HEPES (21063029, Gibco) supplemented with 10% fetal bo-
vine serum (FBS; Gibco) and 100 IU/mL penicillin/100 mg/mL
streptomycin (P/S; Gibco)]. Two days after reaching full con-
fluence (differentiation day 0), 3T3-L1 cells were differentiated
with differentiation medium 1: 3T3-BM containing 0.5 mM
3-isobutyl-1-methylxanthine, 0.25 mM dexamethasone, and
1 mg/mL insulin (all from Sigma-Aldrich). Starting from day 4,
cells were maintained in differentiation medium 2 (3T3-BM
containing 1mg/mL insulin) that was refreshed every 2 to 3 days
until full differentiation on day 12. T37i preadipocytes were
cultured with basal medium [T37i-BM: DMEM/F12 with
L-glutamine (21041025, Gibco) supplemented with 10% FBS,
P/S, and 20 mM HEPES (Gibco)]. Two days after reaching full
confluence (differentiation day 0), T37i cells were differentiated
by adding 2 nM triiodothyronine and 20 nM insulin (both from
Sigma-Aldrich) to T37i-BM. This medium was refreshed every
2 to 3 days until full differentiation on day 9.
Before corticosterone and insulin stimulation, the differ-
entiating cells were steroid-starved for 24 hours by replacing
FBS with dextran-coated charcoal-treated FBS [prepared by
incubating 100 mL of FBS twice with 0.1 g of dextran T250
(Pharmacia, Uppsala, Sweden) and 1 g of activated charcoal
(C5510, Sigma-Aldrich) for 30 minutes, centrifuged, and
sterile filtered]. Three hours before stimulation, the differen-
tiated cells were starved in starvation medium: DMEM (for
3T3-L1) or DMEM/F12 with 20 mM HEPES (for T37i)
supplemented with P/S and 0.2% dextran-coated charcoal-
treated FBS. Subsequently, the cells were stimulated for 24
hours in starvation medium containing 1 mL/mL ethanol
vehicle control, 1 mMcorticosterone, 0.2 mM insulin, or 1 mM
corticosterone and 0.2 mM insulin (both from Sigma-Aldrich).
After stimulation, the cells were used to determine their glu-
cose uptake or immediately stored at 280°C until RNA iso-
lation or protein extraction. In the latter case, cultured media
were also collected, centrifuged, and stored at 220°C for
adipokine measurement by ELISA.
Radioactive glucose uptake
For the glucose uptake studies, the 24-hour corticosterone-
and/or insulin-treated cells were washed with PBS and stimu-
lated with 0, 20, or 100 nM insulin in 0.1% FF-BSA
(03117057001, Roche Diagnostics) in PBS for 15 minutes.
Next, 0.05 mCi of 2-[1-14C]-deoxy-D-glucose (PerkinElmer,
Waltham, MA) in 0.1% FF-BSA was added to the medium.
After an additional 5-minute incubation, the cells were washed
twice with cold PBS, lysed with 0.2% SDS solution (Merck,
Hohenbrunn, Germany), and protein content in cell lysates was
quantified using Advanced protein assay reagent (Cytoskeleton,
Denver, CO). Cell lysates were transferred to a scintillation
glass vial and homogenized in a scintillation cocktail (Opti-
phase HiSafe 3, PerkinElmer Health Sciences, Groningen,
Netherlands). Radioactivity was detected with a liquid scin-
tillation analyzer (Tri-Carb 2910TR, Packard, PerkinElmer)
and reported in counts per minute normalized to protein
content.
Gene expression analysis
RNA was isolated from mouse tissues and cultured cells using
the TriPure isolation reagent (Roche Diagnostics) according to the
manufacturer’s instructions. Contaminating genomic DNA was
removed using RQ1 RNase-free DNase (Promega Corporation,
Figure 1. Compartmental model and formulas used for
calculating blood glucose kinetics. (A) Kinetic model used to
calculate the kinetic parameters of glucose metabolism upon an
IPGTT in mice. Upon injection into the IP compartment, the
injected glucose passes the liver to contribute to the accessible
plasma glucose pool (Qp) and to the inaccessible “tissue” glucose
pool (Qt). Additionally, glucose produced/released by tissues such
as the intestine and liver also contribute to Qp. As such, two rates
of appearances can be distinguished, namely that of exogenous
injected glucose (Raexo) and of endogenous glucose (Raendo). The
Qp is in equilibrium with Qt via two rate constants (k1 and k2).
Disposal of glucose (U) from the Qp can be divided in insulin-
independent glucose-dependent disposal (Uiig) and insulin-
independent constant disposal (Uiic). Disposal from the Qt is the
sum of insulin-dependent constant disposal (Uidc) and insulin-
dependent disposal (Uidi). As with glucose, this model also
presumes two compartments for insulin, namely the accessible
plasma insulin pool (Ip) and the inaccessible tissue insulin pool (It).
(B) Formulas for assessing glucose metabolism indexes and kinetic
parameters. HOMA-IR, an acceptable surrogate index for insulin
resistance when applying a mouse-specific constant (26, 27), was
calculated relative to a median of the vehicle-treated male mice.
b-Cell response was estimated as changes in plasma insulin levels
relative to changes in glucose levels (28). Subscript b refers to a
basal level, subscript 0 refers to an estimated value at time point
0, and Vg indicates the volume of the accessible pool.
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Madison, WI). Purified RNA was quantified with a NanoDrop
8000 spectrophotometer (Thermo Fisher Scientific, Wilmington,
DE). Reverse transcription was performed using the Transcriptor
high-fidelity cDNA synthesis kit (RocheDiagnostics). Quantitative
PCRwas performedusing FastStart Universal SYBRGreenMaster
(Rox) (Roche Diagnostics) with a QuantStudio 7 flex real-time
PCR system (Applied Biosystems, Life Technologies, Carlsbad,
CA). Expression of the tested genes was normalized to the in-
dicated housekeeping genes using the 22DDCT method. Sequences
of the primers for all genes are listed in Table 1.
Protein extraction
Protein was extracted from the insulin-stimulated WAT ex-
plants by mincing the tissues with a micropestle in lysis buffer
containing 50mMHEPES, 150mMNaCl, 10mMEDTA, 2mM
Na3VO4, 20 mMNaF, 1% Triton X-100, phosphatase inhibitor
(P5726, Sigma-Aldrich), and protease inhibitor (cOmplete, Roche
Diagnostics). After centrifugation to remove debris, lysates were
collected. For the cultured adipocytes, cells were lysed in the
aforementioned lysis buffer and sonicated for 10 seconds. Protein
concentrations were quantified relatively to BSA (Sigma-Aldrich)
using the Advanced protein assay reagent (Cytoskeleton).
Western blot analysis
Protein extracts were diluted in Laemmli sample buffer (Bio-
Rad Laboratories, Veenendaal, Netherlands) with 50 mM
dithiothreitol and denatured at 95°C for 5 minutes. A total of
15 mg of protein was electrophoresed on an 8% acrylamide gel
and blotted onto a nitrocellulose membrane. Membranes were
blocked in 3% skim milk powder in PBS for 1 hour at RT and
incubated overnight at 4°C with an Akt antibody [1:1000 (35)]
or a phosphorylated Akt (Ser473) antibody [1:2000 (36)] in
PBS containing 0.1% Tween 20 and 5% BSA. Next, mem-
branes were washed and incubated for 1 hour at RT with an
IRDye 800CW goat anti-rabbit secondary antibody [1:10,000
(37)] in PBS containing 0.1% Tween 20 and 3% skim milk
powder. The Akt and phosphorylated Akt immunoreactivities
were detected with an Odyssey IR imaging system (LI-COR
Biotechnology, Bad Homburg, Germany) and were quantified
using Image Studio Lite software (version 5.2, LI-COR).
Statistical analysis
Data were analyzed and graphs were plotted in GraphPad
Prism for Windows (version 6, GraphPad Software, San Diego,
CA) and IBMSPSS Statistics forWindows (version 24, IBMCorp.,
Armonk, NY). Unless otherwise indicated, differences between
groupswere analyzed by two-wayANOVAwith a Tukey post hoc
test when the interaction of factors was significant or with a
Bonferroni test when the interaction was not significant. P, 0.05
was considered statistically significant [abbreviations for P values:
PC for corticosterone treatment,PI for insulin treatment, PS for sex,
and PT for time (duration) of treatment]. When analyzing the
IPGTT data, the area under the curve (AUC) was calculated
normalized to the fasting level of each animal (26, 38). Unless
specified, data and graphs are shown as mean 6 SEM.
Results
Corticosterone increases nonfasting glucose
concentrations only in male mice
Corticosterone treatment for 2 weeks differentially
affected body weight (BW) of male and female mice
(experiment 1). The corticosterone-treated male mice
were only 1.2 g heavier than vehicle-treated male
mice whereas the corticosterone-treated female mice were
3.5 g heavier than vehicle-treated female mice (repeated
three-way ANOVA: PS3C3T , 0.001; Fig. 2A). Relative
Table 1. Primer Sequences
Gene Forward (50→30) Reverse (50→30)
Adamts1 TGCTCCAAGACATGCGGCTCAG TGGTACTGGCTGGCTTCACTTCC
Adipoq GCACTGGCAAGTTCTACTGCAA GTAGGTGAAGAGAACGGCCTTGT
Cebpb ACGACTTCCTCTCCGACCTCT CGAGGCTCACGTAACCGTAGT
Chrebpb TCTGCAGATCGCGTGGAG CTTGTCCCGGCATAGCAAC
Fkbp5 ATTTGATTGCCGAGATGTG TCTTCACCAGGGCTTTGTC
Foxo1 CTTCAAGGATAAGGGCGACA GACAGATTGTGGCGAATTGA
Irs1 CGATGGCTTCTCAGACGTG CAGCCCGCTTGTTGATGTTG
Irs2 GTGGGTTTCCAGAACGGCCT ATGGGGCTGGTAGCGCTTCA
Klf15 GCGAGAAGCCCTTTGCCT GCTTCACACCCGAGTGAGAT
Lep ACCCCATTCTGAGTTTGTCC TCCAGGTCATTGGCTATCTG
Nr3c1 CCGGGTCCCCAGGTAAAGA TGTCCGGTAAAATAAGAGGCTTG
Nr3c2 ATGGAAACCACACGGTGACCT AGCCTCATCTCCACACACCAAG
Pck1 ATGTGTGGGCGATGACATT AACCCGTTTTCTGGGTTGAT
Pcx GGGATGCCCACCAGTCACT CATAGGGCGCAATCTTTTTGA
Pparg GAAAGACAACGGACAAATCACC GGGGGTGATATGTTTGAACTTG
Slc2a1 GACCCTGCACCTCATTGG GATGCTCAGATAGGACATCCAAG
Slc2a2 CCAGTACATTGCGGACTTCCTT CTTTCCTTTGGTTTCTGGAACTTT
Slc2a4 GTGACTGGAACACTGGTCCTA CCAGCCACGTTGCATTGTAG
Tsc22d3 CAGCAGCCACTCAAACCAGC ACCACATCCCCTCCAAGCAG
Ucp1 GGCCTCTACGACTCAGTCCA TAAGCCGGCTGAGATCTTGT
Actb AAGGCCAACCGTGAAAAGAT GTGGTACGACCAGAGGCATAC
B2m ATCCAAATGCTGAAGAACGG CAGTCTCAGTGGGGGTGAAT
Gapdh TGTCCGTCGTGGATCTGAC CCTGCTTCACCACCTTCTTG
Rn18s GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG
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to BW at implantation, the corticosterone-treated female
mice gained more weight than did the other three groups
(PS3C5 0.002; Fig. 2B). Although vehicle-treated female
mice consumed more food (relative to BW) than did
vehicle-treated male mice, corticosterone treatment sig-
nificantly increased the 24-hour food intake to a com-
parable amount in both sexes (PS , 0.001, PC , 0.001;
Fig. 2C). The 24-hour fecal output was higher in female
than in male mice, was increased by corticosterone
treatment (PS , 0.001, PC , 0.001; Fig. 2D), and was
positively correlated with food intake (r 5 0.93, P ,
0.001; data not shown). Serum corticosterone levels (at
time of euthanization) and fecal corticosterone levels
(2-day average levels between days 12 and 14 of treat-
ment) were measured and confirmed that corticosterone-
treated mice had significantly higher corticosterone levels
in serum and feces than did vehicle-treated mice (PC ,
0.001; Fig. 2E and 2F). Moreover, the corticosterone-
treated male mice tended to have higher corticosterone
levels than did corticosterone-treated female mice, but
levels in vehicle-treated mice were not different between
males and females (Fig. 2E and 2F).
Corticosterone treatment differentially affected NFBG
of male and female mice. Corticosterone increased NFBG
of male mice by approximately twofold whereas it had no
effect on NFBG of female mice (repeated three-way
ANOVA: PS3C3T 5 0.02; Fig. 3A). Measurement of
5-hour FBG after the 2-week treatment period revealed
that female mice had a lower FBG than did male mice,
Figure 2. Effects of corticosterone treatment on BW and energy balance of mice. (A) BW of ad libitum-fed mice before (day 0) and after (days 3
to 14) pellet implantation (repeated three-way ANOVA: PS , 0.001, PC 5 0.11, PT , 0.001, PS3C 5 0.29, PS3T 5 0.02, PC3T , 0.001, PS3C3T
, 0.001). (B) BW changes after 2-wk treatment relative to BW before pellet implantation (PS 5 0.002, PC , 0.001, PS3C 5 0.002). (C) Daily
food intake and (D) fecal production relative to BW, determined during days 12 and 14 of treatment (food intake, PS , 0.001, PC , 0.001,
PS3C 5 0.06; fecal output, PS , 0.001, PC , 0.001, PS3C 5 0.20). (E) Serum corticosterone levels (level at time of euthanization: PS 5 0.14,
PC , 0.001, PS3C 5 0.06). (F) Fecal corticosterone levels (average level during days 12 to 14: PS 5 0.13, PC , 0.001, PS3C 5 0.05). Unless
stated, statistical significance was determined by two-way ANOVA. *P , 0.05, (*)P , 0.10 (tendency to significance), for sex difference between
mice with the same treatment; #P , 0.05, for effect of corticosterone treatment in mice of the same sex, by post hoc test.
Figure 3. Sex-dependent effects of corticosterone treatment on
glucose homeostasis. (A) NFBG levels during days 3 to 14 of
treatment (repeated three-way ANOVA: PS , 0.001, PC , 0.001,
PT , 0.001, PS3C , 0.001, PS3T 5 0.02, PC3T , 0.001, PS3C3T 5
0.02; two-way ANOVA at each time point: PS , 0.05 every time
point, PC 5 0.69 for day 3, PC , 0.05 for days 5 to 14, PS3C ,
0.05 every time point). (B) Fasting blood glucose levels determined
on day 14 of treatment (PS 5 0.01, PC 5 0.008, PS3C 5 0.19).
Unless stated, statistical significance was determined by two-way
ANOVA. *P , 0.05, for sex difference between mice with the same
treatment; #P , 0.05, for effect of corticosterone treatment in mice
of the same sex, by post hoc test.
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and corticosterone treatment reduced the FBG in both
sexes, but more pronounced in female mice (PS 5 0.01,
PC 5 0.008; Fig. 3B). These data suggest that cortico-
sterone treatment disturbs glucose homeostasis more
severely in male than in female mice because only
corticosterone-treated male mice presented with an ele-
vated NFBG.
Differential effects of corticosterone on glucose
tolerance in male and female mice
To investigate the differential effects of high-dose
corticosterone on blood glucose homeostasis in male
and female mice in more detail, mice were subjected to
an IPGTT on day 14 in the second experiment. Also in
this experiment, corticosterone treatment differentially
affected BW of male and female mice (data not shown)
and increased NFBG only in male mice (NFBG day 14:
PS3C , 0.001; Fig. 4A). Compared with the vehicle-
treated mice of the same sex, corticosterone treatment
reduced the 5-hour FBG by 28.1% 6 7.4% in male
mice and by 7.6% 6 4.6% in female mice (unpaired t
test: P 5 0.04; Fig. 4A). FBI was elevated in both sexes
after 7 and 14 days of corticosterone treatment, and the
effect was more pronounced in male than in female mice
Figure 4. Sex-dependent effects of corticosterone treatment on glucose clearance. (A) Nonfasting and 5-h FBG levels (NFBG day 7, PS 5 0.003,
PC 5 0.008, PS3C 5 0.06; FBG day 7, PS 5 0.22, PC 5 0.01, PS3C 5 0.60; NFBG day 14, PS , 0.001, PC , 0.001, PS3C , 0.001; FBG day 14,
PS 5 0.08, PC 5 0.009, PS3C 5 0.07). F indicates the 5-h fasting period on days 0, 7, and 14. (B) Five-hour FBI levels and (C) HOMA-IR
calculated from FBG and insulin levels before (day 0) and after (days 7 and 14) pellet implantation (FBI day 7, PS , 0.001, PC , 0.001,
PS3C 5 0.009; FBI day 14, PS 5 0.001, PC , 0.001, PS3C 5 0.002; HOMA-IR day 7, PS , 0.001, PC , 0.001, PS3C 5 0.04; HOMA-IR day 14,
PS 5 0.01, PC , 0.001, PS3C 5 0.04). (D) Blood glucose levels, (E) changes in blood glucose levels over individual baseline values, (F) baseline-
corrected AUCs of glucose levels, (G) blood insulin levels, (H) changes in blood insulin levels over individual baseline values, and (I) baseline-
corrected AUCs of insulin levels after IP glucose administration in the 2-wk vehicle- or corticosterone-treated mice are shown (AUC glucose
levels, PS , 0.001, PC 5 0.16, PS3C 5 0.03; AUC insulin levels, PS , 0.001, PC , 0.001, PS3C , 0.001). (J) b-Cell response to the IPGTT
(PS 5 0.04, PC , 0.001, PS3C 5 0.12). Statistical significance was determined by two-way ANOVA. *P , 0.05,
(*)P , 0.10 (tendency to
significance), for sex difference between mice with the same treatment; #P , 0.05, for effect of corticosterone treatment in mice of the same
sex, by post hoc test.
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(PS3C , 0.01 for both days; Fig. 4B). Likewise, cortico-
sterone treatment increased the homeostatic model as-
sessment of insulin resistance (HOMA-IR) values more
profoundly inmale mice than in femalemice (PS3C, 0.05
for both days; Fig. 4C). These data underscore that
corticosterone-induced insulin resistance is more pro-
nounced in male than in female mice.
After the IP administration of glucose, peak glucose
levels of corticosterone-treated male mice were lower
than in vehicle-treated males. However, corticosterone-
treated male mice showed a delayed glucose clearance,
and glucose levels did not return to baseline levels
(Fig. 4D and 4E). As a result, baseline-corrected AUC
values were slightly but not significantly increased in the
corticosterone-treated males (PS3C 5 0.03; Fig. 4F). In
contrast, in corticosterone-treated female mice the blood
glucose levels were blunted, resulting in a significantly
reduced baseline-corrected AUC value (Fig. 4D–4F).
Blood insulin levels after IPGTT were markedly differ-
ent between the groups, mainly due to the elevated
baseline FBI upon corticosterone treatment (Fig. 4G).
Interestingly, the rise in blood insulin levels upon glucose
injection was greater in the corticosterone-treated male
mice than in the other three groups (PS3C , 0.001;
Fig. 4H and 4I). Calculated from the glucose and insu-
lin AUC, the b-cell response was largely increased by
Figure 5. Glucose kinetic parameters from stable isotope-labeled glucose analyses. (A) Blood [U-13C6]-D-glucose levels with model-fitted line
plots after IP stable isotope-labeled glucose administration in the 2-wk vehicle- or corticosterone-treated mice. This plot was used for
calculating following glucose kinetic parameters. (B) Glucose clearance rate and (C) endogenous glucose production at basal state (before
glucose administration; GCR, PS , 0.001, PC 5 0.42, PS3C 5 0.04; EGP, PS 5 0.003, PC 5 0.06, PS3C 5 0.006). (D) Bioavailability of the
injected glucose in the accessible pool of the minimal mouse model (PS 5 0.18, PC , 0.001, PS3C 5 0.18). (E) Stacked area plots
demonstrating utilization of the injected glucose, separated into independent, glucose-mediated, and insulin-mediated fluxes. (F) AUCs of
total glucose utilization (AUC total flux, PS 5 0.08, PC , 0.001, PS3C 5 0.26). (G) Relative percentages of each glucose utilization flux (PS3C
, 0.05 for all fluxes). (H) Insulin sensitivity reflecting the clearance of injected glucose by endogenous insulin secretion (PS , 0.001, PC ,
0.001, PS3C 5 0.10). Statistical significance was determined by two-way ANOVA. *P , 0.05, for sex difference between mice with the same
treatment; #P , 0.05, for effect of corticosterone treatment in mice of the same sex, by post hoc test.
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corticosterone treatment and was higher in female mice
than in male mice (PS 5 0.04, PC , 0.001; Fig. 4J).
Using the enrichment of blood [U-13C6]-D-glucose
(Fig. 5A), the effects of corticosterone treatment on the
glucose clearance rate (GCR) and the EGP at baseline
(before glucose injection) can be calculated. The GCR
was higher in female mice than in male mice, and cor-
ticosterone treatment tended to sex-dependently affect
GCR, namely a reduction in male mice and an increase in
female mice (PS3C 5 0.04; Fig. 5B). The EGP was re-
duced by corticosterone treatment in male mice but was
unaffected in female mice (PS3C 5 0.006; Fig. 5C). The
factors contributing to blood glucose levels after the
injected bolus can also be assessed. First, the bio-
availability of the injected glucose was reduced by cor-
ticosterone treatment, but sex-independently (PC ,
0.001; Fig. 5D). Second, detailed analysis of the clear-
ance of the injected glucose revealed that the glucose-
mediated flux, the insulin-mediated flux, and the in-
dependent flux were in general reduced by corticosterone
treatment in both male and female mice (AUC total flux:
PC , 0.001; Fig. 5E and 5F). Interestingly, the per-
centage contribution of each flux was sex-dependently
altered by corticosterone treatment, shifting toward
insulin-mediated flux for male mice but toward in-
dependent flux for female mice (PS3C , 0.05 for all
fluxes; Fig. 5G). Finally, the insulin sensitivity index
(insulin-mediated glucose clearance) was markedly re-
duced by corticosterone treatment, and female mice
had a greater insulin sensitivity index than did male mice
(PS , 0.001, PC , 0.001; Fig. 5H). This finding once
again underscores that corticosterone-induced insulin
resistance is more pronounced in male mice than in fe-
male mice.
Sex-differential effects of corticosterone on
WAT morphology
Adipose tissue is one of the glucose-consuming tissues,
and we previously reported marked effects of corticoste-
rone treatment on adipose tissue depots in male mice (39).
Because the current data suggest that glucose clearance is
differentially affected by corticosterone treatment in male
and female mice, we next investigated the effects of cor-
ticosterone on male and female adipose tissues in more
detail. Corticosterone treatment altered many aspects of
WAT and BATmorphology and function with some clear
differences between male and female mice. The visceral
depot gWAT had a substantially greater mass in vehicle-
treated malemice than in vehicle-treated female mice. This
sex-dependent pattern disappeared after corticosterone
treatment, as corticosterone-treated male and female mice
had a comparable gWAT mass (PS3C 5 0.001; Fig. 6A).
Two subcutaneous depots, iWAT and aWAT, also gained
more mass upon corticosterone treatment, but there was
no significant sex difference (PC, 0.001 for both depots,
PS3C 5 0.04 for iWAT; Fig. 6B and 6C). Corticosterone
treatment noticeably elevated the total WAT mass (the
sum of the aforementioned WAT masses) without a sig-
nificant sex difference (PS3C 5 0.006; Fig. 6D).
Because the mode of WAT expansion (hypertrophy or
hyperplasia) can explain WAT functions and adapta-
tions, the histologies of gWAT (Fig. 6E) and aWAT
(Fig. 6F) after corticosterone treatment were studied.
Female mice had a remarkably smaller gWAT adipocyte
size than did male mice, and corticosterone treatment
enlarged gWAT adipocyte size in both sexes (PS, 0.001,
PC , 0.001; Fig. 6G). The cross-sectional area of aWAT
adipocytes was also smaller in female mice than in male
mice, and corticosterone treatment increased the aWAT
adipocyte size in both sexes (PS 5 0.008, PC , 0.001;
Fig. 6H).
Corticosterone treatment induces significant changes
in gene expression in a partly depot- and sex-dependent
manner. The mRNA expression of Nr3c1 encoding the
GC receptor (GR) in gWAT was lower in female mice
than in male mice, whereas its expression in iWAT was
higher in female mice than in male mice. Corticosterone
treatment reduced Nr3c1 mRNA expression in both
depots of both sexes (Table 2). The mRNA expression
of the GR target genes Fkbp5 and Tsc22d3 was signif-
icantly induced by corticosterone treatment in both de-
pots with a general trend of higher expression in
corticosterone-treated male depots than in female depots
(Table 2). Although corticosterone and sex of the mice
did not affect the mRNA expression of Nr3c2 encoding
the mineralocorticoid receptor (MR) in gWAT, its ex-
pression in iWAT was strikingly higher in vehicle-treated
female mice than in male mice. However, this sex-
differential pattern in iWAT disappeared upon cortico-
sterone treatment because it reduced Nr3c2 mRNA
expression in female mice only (Table 2).
In gWAT, mRNA expression of the adipogenic
transcription factors Cebpb and Pparg was generally
elevated by corticosterone treatment in both sexes. In
iWAT, expression of both transcription factors tended to
be higher in female mice than in male mice (Table 2).
ADAMTS1, an extracellular protein secreted from ma-
ture adipocytes, together with Adamts1 mRNA expres-
sion has been considered a marker of the hyperplastic
limitation in WAT because it inhibits the generation of
new adipocytes from adipocyte precursor cells (40). In
gWAT, female mice had a lower Adamts1 mRNA ex-
pression than did male mice, and corticosterone treat-
ment induced its expression in both sexes. However,
corticosterone treatment induced Adamts1 mRNA ex-
pression by sevenfold in iWAT of male mice but did
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not significantly affect the expression in female mice
(Table 2). Of note,Adamts1mRNA expression in gWAT
was on average 11-fold higher than in iWAT (data not
shown).
Sex-differential effects of corticosterone on
adipokine secretion
Apart from energy storage as lipid droplets, adipose
tissue depots secrete a number of adipokines into the
circulation. Serum leptin concentrations were strongly
elevated after corticosterone treatment in both male and
female mice (PC , 0.001; Fig. 7A). The serum concen-
trations of total adiponectin were in general higher in
female mice than in male mice and were increased upon
corticosterone treatment, especially in femalemice (PS3C5
0.005; Fig. 7B). Serum concentrations of HMW adipo-
nectin, the metabolically active adiponectin isoform, were
also elevated by corticosterone treatment (PS3C 5 0.004;
Fig. 7C). The HMW/total adiponectin ratio did not differ
between the sexes but was significantly higher after cor-
ticosterone treatment (PC , 0.001; Fig. 7D). The
adiponectin/leptin (A/L) ratio, a promising index for
assessing insulin sensitivity (41), was higher in vehicle-
treated female mice than in male mice, but this sex
difference was attenuated and reduced to a similar low
A/L ratio after corticosterone treatment (PS3C 5 0.007;
Figure 6. Sex differences in WAT mass and morphology upon corticosterone treatment. (A–D) gWAT, iWAT, aWAT, and total WAT mass
relative to BW of the 2-wk vehicle- or corticosterone-treated mice (gWAT, PS 5 0.12, PC , 0.001, PS3C 5 0.001; iWAT, PS 5 0.33, PC , 0.001,
PS3C 5 0.04; aWAT, PS 5 0.93, PC , 0.001, PS3C 5 0.07; total WAT mass, PS 5 0.80, PC , 0.001, PS3C 5 0.006). (E and F) Hematoxylin and
eosin–stained gWAT and aWAT. Experimental group abbreviations: FC, female corticosterone; FV, female vehicle; MC, male corticosterone; MV,
male vehicle. Scale bars, 100 mm. (G and H) gWAT and aWAT adipocyte sizes (gWAT, PS , 0.001, PC , 0.001, PS3C 5 0.12; aWAT, PS 5
0.008, PC , 0.001, PS3C 5 0.58). Statistical significance was determined by two-way ANOVA. *P , 0.05,
(*)P , 0.10 (tendency to significance),
for sex difference between mice with the same treatment; #P , 0.05, for effect of corticosterone treatment in mice of the same sex, by post hoc
test.
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Fig. 7E). The HMW adiponectin/leptin ratio showed a
similar pattern (PS , 0.001, PC , 0.001, PS3C 5 0.001;
data not shown).
The changes in leptin concentrations were also re-
flected by changes in gene expression. Corticosterone
treatment induced Lep mRNA expression in gWAT and
iWAT of both sexes, which was more pronounced in
corticosterone-treated male mice than in female mice
(Table 2). In contrast, corticosterone treatment reduced
Adipoq mRNA expression in both depots of both sexes.
Furthermore, female mice tended to have a higher Adi-
poq mRNA expression in iWAT than did male mice
(Table 2). Note that Lep mRNA expression in gWAT
was on average fivefold higher whereas Adipoq mRNA
expression was 0.7-fold lower than in iWAT (data not
shown).
Corticosterone treatment reduces BAT activity in
both male and female mice
In both male and female mice, corticosterone treat-
ment increased BAT mass (PC , 0.001; Fig. 8A) and
induced lipid accumulation and unilocular rearrange-
ment in BAT (Fig. 8B). The mRNA expression ofUcp1, a
classical BAT thermogenic gene, was reduced by corti-
costerone treatment in both sexes (Table 3). Although
corticosterone treatment tended to reduce mRNA ex-
pression of Nr3c1 without a sex-dependent pattern in
BAT, it significantly induced expression of the GR target
genes Fkbp5 and Tsc22d3 in both sexes, albeit less
pronounced in female mice than in male mice (Table 3).
The mRNA expression of Nr3c2 was lower in female
mice than in male mice without an obvious effect by
corticosterone treatment (Table 3).
Lep mRNA expression in BAT of female mice tended
to be lower than that of male mice, and corticosterone
treatment strongly induced the expression in both sexes
by .35-fold (Table 3). However, Adipoq mRNA ex-
pression in BAT was not significantly affected by corti-
costerone treatment in both sexes (Table 3).
Elevated concentrations of leptin and adiponectin
are likely due to hyperinsulinemia, not a direct effect
of corticosterone
To investigate whether the elevated serum leptin and
adiponectin levels upon corticosterone treatment are
caused directly by corticosterone or indirectly as a result
of the compensatory hyperinsulinemia, in vitro studies
using 3T3-L1 white adipocytes and T37i brown adipo-
cytes were performed. In 3T3-L1 cells, corticosterone
reduced whereas insulin induced Lep mRNA expression
(Table 4). Leptin production and secretion by 3T3-L1
cells were also significantly stimulated by insulin treat-
ment (Table 4). Although both insulin and corticosterone
reduced Adipoq mRNA expression in 3T3-L1 cells,
cotreatment of insulin and corticosterone attenuated the
inhibitory effect of corticosterone on Adipoq mRNA
expression (Table 4). In contrast, insulin significantly
Figure 7. Serum adipokine levels. (A) Serum leptin levels and (B and C) serum total adiponectin and HMW isoform levels of the 2-wk vehicle- or
corticosterone-treated mice (leptin, PS 5 0.64, PC , 0.001, PS3C 5 0.89; total adiponectin, PS , 0.001, PC , 0.001, PS3C 5 0.005; HMW
adiponectin, PS 5 0.008, PC , 0.001, PS3C 5 0.004). (D) Ratio of the HMW isoform to the total adiponectin levels (PS 5 0.12, PC , 0.001,
PS3C 5 0.37). (E) Ratio of adiponectin to leptin levels, illustrated on a logarithmic scale (PS , 0.001, PC , 0.001, PS3C 5 0.007). Statistical
significance was determined by two-way ANOVA. *P , 0.05, for sex difference between mice with the same treatment; #P , 0.05, for effect of
corticosterone treatment in mice of the same sex, by post hoc test.
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increased whereas corticosterone reduced the total adipo-
nectin production in 3T3-L1 cells, and adiponectin secre-
tion tended to be increased by corticosterone only (Table 4).
In T37i cells, corticosterone reduced whereas insulin
strongly induced Lep mRNA expression (Table 4).
Likewise, leptin production and secretion by T37i cells
were stimulated by insulin treatment and cotreatment of
corticosterone and insulin, while corticosterone treat-
ment alone marginally reduced its production (Table 4).
Although corticosterone reduced Adipoq and insulin
did not alter Adipoq mRNA expression in T37i cells,
cotreatment of insulin and corticosterone attenuated the
inhibitory effect of corticosterone treatment (Table 4).
Furthermore, whereas insulin treatment only increased
intracellular adiponectin but did not affect the total pro-
duction, corticosterone treatment reduced total adiponectin
production but increased its secretion significantly
(Table 4). Apart from adiponectin production in brown
adipocytes, these data suggest that the elevated adipokine
levels of corticosterone-treated mice were more likely
caused by the high insulin level than by corticosterone
treatment itself.
Corticosterone treatment reduces insulin-
stimulated Akt phosphorylation in WAT
Insulin induces glucose uptake in WATs through Akt
phosphorylation and subsequently GLUT4 translocation
(42). To determine insulin signaling in WATs of vehicle-
and corticosterone-treated mice, gWAT (a visceral depot)
and iWAT (a subcutaneous depot) explants were stim-
ulated with insulin and Akt phosphorylation was de-
termined. Corticosterone treatment reduced baseline and
Figure 8. BAT mass and morphology upon corticosterone treatment. (A) BAT mass relative to BW of the 2-wk vehicle- or corticosterone-treated
mice (PS 5 0.68, PC , 0.001, PS3C 5 0.12). (B) Hematoxylin and eosin–stained BAT. Experimental group abbreviations: FC, female
corticosterone; FV, female vehicle; MC, male corticosterone; MV, male vehicle. Scale bar, 100 mm. Statistical significance was determined by
two-way ANOVA. #P , 0.05, for effect of corticosterone treatment in mice of the same sex, by post hoc test.
Table 3. mRNA Expression in BAT
Genes Sig. M Veh M Cort F Veh F Cort
Thermogenic gene
Ucp1 C,3 1.00 6 0.16 0.80 6 0.21 1.61 6 0.25 0.50 6 0.15a
GR, MR, and GR target genes
Nr3c1 (C) 1.00 6 0.11 0.86 6 0.10 0.97 6 0.13 0.68 6 0.09
Fkbp5 S,C,3 1.00 6 0.12 43.82 6 4.34a 0.64 6 0.06 30.00 6 4.79a,b
Tsc22d3 C,3 1.00 6 0.08 5.05 6 0.35a 1.36 6 0.13 3.89 6 0.41a,b
Nr3c2 S 1.00 6 0.07 0.89 6 0.11 0.59 6 0.12b 0.76 6 0.15
Adipokine production
Lep (S),C 1.00 6 0.36 38.56 6 7.49a 0.12 6 0.03 23.54 6 4.55a,c
Adipoq — 1.00 6 0.10 0.98 6 0.14 1.23 6 0.15 0.82 6 0.09
Glucose transport
Irs1 — 1.00 6 0.21 1.19 6 0.11 2.10 6 0.78 1.12 6 0.21
Slc2a1 — 1.00 6 0.15 1.23 6 0.19 0.74 6 0.09 1.00 6 0.15
Slc2a4 — 1.00 6 0.17 1.00 6 0.13 0.84 6 0.08 1.10 6 0.10
Chrebpb 3 1.00 6 0.19 0.63 6 0.13 0.44 6 0.07c 0.92 6 0.18
Gene expression was normalized to Actb and Rn18s expression and expressed relative to the vehicle-treated male mice. Sig. indicates significant effects
(P , 0.05) analyzed with two-way ANOVA. Symbols in parentheses [e.g., (C)] indicate a tendency to significance (P , 0.10).
Abbreviations: C, corticosterone treatment; S, sex; 3, interaction of corticosterone treatment and sex.
aP , 0.05, for effect of corticosterone treatment in mice of the same sex, by post hoc test.
bP , 0.05, for sex difference between mice with the same treatment, by post hoc test.
cP , 0.10 (tendency to significance), for sex difference between mice with the same treatment, by post hoc test.
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insulin-stimulated Akt phosphorylation without a sex-
dependent pattern in both gWAT and iWAT explants
(repeated 3-way ANOVA: PC3I, 0.05 in both explants;
Fig. 9).
Corticosterone reduces whereas insulin induces
glucose uptake, but both cause insulin resistance
in WAT
To address the effects of corticosterone treatment on
adipose tissue glucose homeostasis, we assessed the ad-
ipose tissue mRNA expression of genes related to glucose
transport. Corticosterone treatment did not affect mRNA
expression of Irs1, the gene encoding the insulin recep-
tor, in gWAT and BAT, but it reduced its expression in
iWAT (Tables 2 and 3). In gWAT, the mRNA expression
of the glucose transporter 4 [Slc2a4 (Glut4)], an insulin-
dependent glucose transporter, and the glucose trans-
porter 1 [Slc2a1 (Glut1)], a basal glucose transporter,
were in general increased by corticosterone treatment
(Table 2). In iWAT, corticosterone treatment reduced
Slc2a1 expression but tended to increase Slc2a4 ex-
pression (Table 2). In contrast, corticosterone treatment
did not significantly affect Slc2a1 and Slc2a4 mRNA
expression in BAT (Table 3). Finally, we analyzed the
expression of Mlxipl variant b (or called Chrebpb), a
gene whose transcription is regulated by the carbohydrate-
responsive element-binding protein (ChREBP; also known
as MLX interacting protein-like) because it can be con-
sidered a readout of intracellular glucose concentrations
(43). Corticosterone treatment increased Chrebpb
expression in gWAT and iWAT, but not in BAT, sug-
gestive of an increased glucose uptake after cortico-
sterone treatment in both WAT depots (Tables 2 and
3). Of note, Chrebpb expression in the iWAT depot
was significantly induced by corticosterone treatment
only in female mice due to the sex-differential baseline
expression.
To determine whether the increased uptake of glu-
cose in WAT upon corticosterone treatment is due to
corticosterone per se and/or the high plasma insulin
concentrations, we measured the insulin-stimulated
glucose uptake in 3T3-L1 and T37i cells pretreated
for 24 hours with corticosterone and/or insulin. In 3T3-
L1 cells, pretreatment with corticosterone (PC) inhibited
whereas pretreatment with insulin (PI) stimulated basal
glucose uptake (PPC3PI 5 0.009; Fig. 10A). Note,
however, that the co-pretreatment of corticosterone and
insulin resulted in a 34% lower basal glucose uptake
than did insulin pretreatment alone. The insulin-
stimulated glucose uptake pattern was affected by
pretreatment with corticosterone, pretreatment with in-
sulin, and stimulatory insulin (SI) (repeated three-way
ANOVA: PPC3PI3SI 5 0.001; Fig. 10A). Pretreatment
with corticosterone and insulin alone or in combination
significantly inhibited the insulin-induced glucose uptake
(Fig. 10A).
For T37i cells, the basal glucose uptake was decreased
by pretreatment with corticosterone but increased by
Figure 9. Insulin-stimulated Akt phosphorylation in WAT explants. (A and B) Akt phosphorylation level in (A) gWAT and (B) iWAT of the vehicle-
or corticosterone-treated mice, ex vivo stimulated with insulin (gWAT, PS 5 0.99, PC 5 0.005, PI , 0.001, PS3C 5 0.99, PS3I 5 0.95, PC3I 5
0.02, PS3C3I 5 0.39; iWAT, PS 5 0.91, PC 5 0.004, PI , 0.001, PS3C 5 0.45, PS3I 5 0.97, PC3I 5 0.02, PS3C3I 5 0.57). Akt phosphorylation
level was normalized to total Akt and expressed relative to the level of vehicle-treated male explants. A representative blot is shown of three
biological samples per group. Statistical significance was determined by repeated three-way ANOVA with post hoc Tukey test: letters a, b, and c
denote significant group differences (P , 0.05).
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pretreatment with insulin (PPC 5 0.05, PPI , 0.001;
Fig. 10B). The insulin-stimulated glucose uptake pattern
was increased by stimulatory insulin, but it was not sig-
nificantly altered by pretreatment with corticosterone or
pretreatment with insulin, reflecting an insulin-sensitive
state of the corticosterone- or insulin-pretreated T37i cells
(repeated three-way ANOVA: PSI , 0.001; Fig. 10B).
These data suggest that corticosterone and high-dose in-
sulin induce insulin resistance mainly in white adipocytes,
but not in brown adipocytes.
Effect of corticosterone treatment on gene
expression in skeletal muscle
Not only adipose tissues, but also skeletal muscle is an
important glucose-consuming organ that contributes to
whole-body GCR, especially at the postprandial state,
and GCs have been shown to reduce glucose uptake in
the muscle by counteracting the effect of insulin (1, 4).
We therefore investigated whether corticosterone treat-
ment affected the gene expression profile in skeletal
muscle in a sex-dependent manner. The expressions of
Nr3c1 (GR) and Nr3c2 (MR) were not significantly
different between male and female mice and were not
affected by corticosterone treatment (Table 5). Corti-
costerone treatment significantly increased the mRNA
expression of the GR target genes Fkpb5 and Tsc22d3 in
both sexes (Table 5).
Another hallmark of GC excess is GC-mediated
muscle atrophy by reducing muscle protein synthesis
and degrading muscle proteins. Corticosterone treatment
strongly upregulated the mRNA expression of the muscle
atrophy-related genes Foxo1 and Klf15 in both male and
female mice (Table 5).
Vehicle-treated female mice had a higher Irs1 mRNA
expression than did vehicle-treated male mice, but cor-
ticosterone treatment reduced Irs1 mRNA expression
to a similar level in male and female mice (Table 5).
Whereas the expression of Slc2a1 and Slc2a4mRNAwas
not significantly affected by corticosterone treatment,
Chrebpb mRNA expression was remarkably elevated by
corticosterone treatment in both sexes (Table 5).
Effect of corticosterone treatment on gene
expression in liver
We also determined hepatic gene expressions of the
vehicle- and corticosterone-treated mice because the liver
is the central organ regulating whole-body glucose ho-
meostasis, especially in the fasting state when hepatic
gluconeogenesis is crucial to maintain euglycemia (1, 4).
Nr3c1 mRNA expression tended to be higher in female
mice than in male mice but was not significantly affected
by corticosterone treatment (Table 6). However, corti-
costerone treatment clearly induced Fkpb5 and Tsc22d3
mRNA expression in both sexes (Table 6). Regarding
transcriptional regulation of genes encoding gluconeo-
genic enzymes, corticosterone treatment upregulated the
mRNA expression of Pck1 (phosphoenolpyruvate car-
boxykinase 1, also known as PEPCK) and Pcx (pyruvate
carboxylase) in a sex-independent manner (Table 6).
Whereas Irs1 mRNA expression was not significantly
affected by sex or corticosterone treatment, Irs2 mRNA
expression was higher in vehicle-treated female mice than
in male mice and was reduced by corticosterone treat-
ment to a comparable level in both sexes (Table 6).
Corticosterone treatment induced transcription of Slc2a2
(also known as Glut2), a major glucose transporter for
hepatic glucose uptake, in male mice only (Table 6).
Figure 10. Insulin-stimulated radioactive glucose uptake in corticosterone- and/or insulin-treated 3T3-L1 and T37i adipocytes. (A) Differentiated
3T3-L1 white adipocytes and (B) differentiated T37i brown adipocytes pretreated with corticosterone (PC) and/or insulin (PI) for 24 h were
stimulated with insulin (SI) at the indicated concentrations for 15 min, and subsequently 2-[1-14C]-deoxy-D-glucose was added to determine
glucose uptake (3T3-L1, PPC 5 0.03, PPI 5 0.09, PSI , 0.001, PPC3PI 5 0.60, PPC3SI 5 0.08, PPI3SI , 0.001, PPC3PI3SI 5 0.001; T37i, PPC 5
0.22, PPI 5 0.16, PSI , 0.001, PC3PI 5 0.77, PPC3SI 5 0.46, PPI3SI 5 0.17, PPC3PI3SI 5 0.15). Data from three independent experiment were
plotted in counts per minute, relative to protein content (mg) of each sample. Pretreatment condition abbreviations: CORT, corticosterone;
CORT1INS, cotreatment with corticosterone and insulin; INS, insulin. Statistical significance was determined by repeated three-way ANOVA.
1P , 0.05, (1)P , 0.10 (tendency to significance), for difference from baseline uptake of control condition; #P , 0.05, for effect of the
stimulatory insulin from its baseline uptake, by post hoc Dunnett test.
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Furthermore, corticosterone treatment increased Chrebpb
mRNA expression in both sexes, but this increase tended
to be higher in corticosterone-treated male mice than in
female mice (Table 6).
Discussion
This study demonstrates that a high-dose corticosterone
treatment causes insulin resistance in both sexes ofmice, but
with a more severe phenotype in male than in female mice.
Our results also show that corticosterone-treated female
mice displayed amore protective feature inWAT expansion
and adipokine secretion than did corticosterone-treated
male mice.
The 2-week treatment with high-dose corticosterone
induced an insulin-resistant state more potently in males
than in females, which was confirmed by high FBI
concentrations, and hence an increase in HOMA-IR
levels. Moreover, in-depth analyses indicated that glu-
cose metabolismwas more disturbed in male mice than in
female mice. First, the corticosterone-induced increase in
FBI levels slightly decreased FBG levels only in female
mice. Second, corticosterone treatment elevated NFBG
levels in male mice but not in female mice, resembling
Table 6. mRNA Expression in Liver
Genes Sig. M Veh M Cort F Veh F Cort
GR, MR, and GR target genes
Nr3c1 (S) 1.00 6 0.05 1.08 6 0.08 1.41 6 0.17a 1.20 6 0.22
Fkbp5 C 1.00 6 0.22 40.38 6 7.71b 4.09 6 0.68 31.63 6 6.59b
Tsc22d3 C 1.00 6 0.01 5.27 6 0.57b 1.55 6 0.25 4.50 6 0.51b
Nr3c2 — 1.00 6 0.09 1.00 6 0.16 1.15 6 0.13 1.22 6 0.31
Gluconeogenesis
Pck1 C 1.00 6 0.13 2.30 6 0.33b 1.26 6 0.18 2.23 6 0.23b
Pcx (3),C 1.00 6 0.05 1.92 6 0.25c 1.03 6 0.06 1.41 6 0.15
Glucose transport
Irs1 — 1.00 6 0.15 0.70 6 0.11 0.99 6 0.09 1.02 6 0.10
Irs2 3,S,C 1.00 6 0.09 0.55 6 0.02b 1.88 6 0.05d 0.74 6 0.07b
Slc2a2 3,C 1.00 6 0.09 1.84 6 0.22b 1.43 6 0.17 1.43 6 0.19
Chrebpb (S),C 1.00 6 0.11 1.69 6 0.10b 0.97 6 0.05 1.31 6 0.18a,c
Gene expression was normalized to Actb and Rn18s expression and expressed relative to the vehicle-treated male mice. Sig. indicates significant effects
(P , 0.05) analyzed with two-way ANOVA. Symbols in parentheses [e.g., (S)] indicate a tendency to significance (P , 0.10).
Abbreviations: C, corticosterone treatment; S, sex; 3, interaction of corticosterone and sex.
aP , 0.10 (tendency to significance), for sex difference between mice with the same treatment, by post hoc test.
bP , 0.05, for effect of corticosterone treatment in mice of the same sex, by post hoc test.
cP , 0.10 (tendency to significance), for effect of corticosterone treatment in mice of the same sex, by post hoc test.
dP , 0.05, for sex difference between mice with the same treatment, by post hoc test.
Table 5. mRNA Expression in Skeletal Muscle
Genes Sig. M Veh M Cort F Veh F Cort
GR, MR, and GR target genes
Nr3c1 — 1.00 6 0.17 0.90 6 0.06 0.88 6 0.20 0.91 6 0.15
Fkbp5 S,C,3 1.00 6 0.10 18.11 6 1.06a 0.69 6 0.13 12.49 6 2.29a,b
Tsc22d3 C 1.00 6 0.20 3.99 6 0.67a 1.07 6 0.21 4.30 6 0.95a
Nr3c2 — 1.00 6 0.10 1.36 6 0.29 1.22 6 0.34 1.21 6 0.13
Muscle atrophy
Foxo1 C 1.00 6 0.13 12.80 6 2.11a 1.30 6 0.30 14.25 6 3.46a
Klf15 C 1.00 6 0.18 2.70 6 0.63a 1.22 6 0.24 2.23 6 0.36
Glucose transport
Irs1 S,C,3 1.00 6 0.17 0.66 6 0.10 2.24 6 0.45b 0.61 6 0.19a
Slc2a1 — 1.00 6 0.27 1.60 6 0.61 1.08 6 0.13 0.81 6 0.26
Slc2a4 — 1.00 6 0.08 1.04 6 0.09 1.01 6 0.16 1.24 6 0.12
Chrebpb C 1.00 6 0.35 13.06 6 1.22a 0.80 6 0.06 18.04 6 10.57a
Gene expression was normalized toGapdh and Rn18s expression and expressed relative to the vehicle-treated male mice. Sig. indicates significant effects
(P , 0.05) analyzed with two-way ANOVA.
Abbreviations: C, corticosterone treatment; S, sex; 3, interaction of corticosterone treatment and sex.
aP , 0.05, for effect of corticosterone treatment in mice of the same sex, by post hoc test.
bP , 0.05, for sex difference between mice with the same treatment, by post hoc test.
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the early pathognomonic postprandial hyperglycemia
as a sign of GC-induced diabetes mellitus in humans (44).
Third, the increases in glucose and insulin levels after an
IPGTT were more severe in corticosterone-treated male
mice than in female mice.
To gain insight into the underlying mechanisms of the
corticosterone-induced insulin resistance, especially the
resemblance of a postprandial-like state, we determined
EGP and GCR using an IPGTT enriched with a stable
isotope tracer, that is, [U-13C6]-D-glucose. In contrast to
the more severe whole-body insulin resistance in the
corticosterone-treated male mice, the high blood insulin
concentrations upon corticosterone treatment resulted in
lower glucose production in male mice but not in female
mice. Because GCs stimulate and insulin suppresses he-
patic gluconeogenesis, it is hard to separate the contri-
bution of these two factors in the control of EGP. Quinn
et al. (45) have shown that female mice have a higher
hepatic susceptibility to GCs. Thus, more pronounced
actions of GCs in female mice might overrule the in-
hibitory effect of insulin on EGP or, alternatively, the
FBG levels of corticosterone-treated mice were at their
lowest limit, which requires EGP to prevent symptomatic
hypoglycemia. Corticosterone treatment had opposite
effects on GCR in male and female mice. GCR tended to
increase in female mice but tended to decrease in male
mice. These findings confirm that peripheral insulin re-
sistance was more severe in corticosterone-treated males
than in corticosterone-treated females because the ele-
vated insulin levels by corticosterone treatment should
have increased GCR substantially in both sexes. Alto-
gether, our data show that the sex-differential effects of
high-dose corticosterone treatment on insulin sensitivity
were mainly driven by the more pronounced insulin
resistance of peripheral tissues in male mice.
Remarkably,we observed that the BWof corticosterone-
treated female mice in this study increased much more
than that of corticosterone-treated male mice. This seems
in contrast to the more severe insulin resistance in
corticosterone-treated male mice, as weight gain usually
links with an increase in insulin resistance (46, 47).
The more pronounced increase in BW in female mice
could be explained by the well-known effect of GC-
induced muscle atrophy (48). Because lean mass of
male C57BL/6J mice at this age is in general 6 g heavier
than that of female mice (49), corticosterone treatment
could lead to a substantial reduction in muscle mass in
male mice and thereby mask an increase in fat mass,
resulting in an unchanged total BW. Nevertheless, we
observed that the fold increase in WAT mass was greater
upon corticosterone treatment in female mice than in
male mice, suggesting a sex-dependent expansion rate of
WAT to GCs.
WAT stores lipid and can expand by enlarging cell size
(hypertrophy), increasing cell number (hyperplasia), or a
combination of both (50, 51). Hypertrophic expansion is
consideredmore detrimental than hyperplasic expansion,
as hypertrophy is associated with reduced insulin sen-
sitivity (50). Adipose tissue expansion generally shows a
depot-related pattern; that is, subcutaneousWAT is more
hyperplastic than visceral WAT (51). Our finding that
corticosterone-treated female mice tended to have larger
WAT depots but smaller adipocytes, together with a
lower mRNA expression of Adamts1 and Lep, than do
corticosterone-treated male mice suggests that female
mice displayed more hyperplastic expansion in WATs
than did male mice upon corticosterone treatment. This
is in accordance with a previous study showing that
corticosterone-induced adipocyte expansion was greater
in ovariectomized female rats than in sham-operated
female rats, which suggests a role for sex steroids in
the sex difference in adipose depot expandability (52).
Besides its fundamental function as an energy reservoir,
WAT secretes a number of adipokines that are essential
mediators regulating systemic energy homeostasis and are
also linked with the mode of expansion as previously
discussed (50, 53).We found that corticosterone treatment
increased Lep expression in gWAT, iWAT, and BAT and
increased circulating leptin levels in both sexes of mice,
which was linked with an increasedWATmass and was in
line with other studies (54). Moreover, the increased food
intake after corticosterone treatment might indicate leptin
resistance in the corticosterone-treated mice (53, 54).
Circulating levels of total and HMW adiponectin and the
A/L ratio are considered reliable indicators for assessing
adipocyte dysfunction and metabolic disorder because
adiponectin levels decline in obesity and insulin resis-
tance (41, 50, 55, 56). Also in our study, both the A/L
ratio and HMW adiponectin/leptin ratio were reduced in
the corticosterone-treated mice. Nevertheless, circulating
levels of total adiponectin and HMW adiponectin were
elevated upon corticosterone treatment, especially in
female mice. In accordance with our data, a previous
study in male mice showed that prednisolone treatment
increased plasma adiponectin levels and the effect was
more pronounced when administering prednisolone to
the castrated mice (57). Expression of Adipoq in gWAT,
iWAT, and BAT of corticosterone-treatedmice, however,
was lower or tended to be lower than that of the vehicle-
treatedmice. This contradictory effect on gene expression
and total circulating protein level might be explained by
the compensatory effect of insulin because our in vitro
studies in cultured 3T3-L1 white adipocytes and T37i
brown adipocytes revealed opposite effects of insulin and
corticosterone on the production and secretion of adi-
ponectin. More comprehensive in vivo studies are needed
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to elucidate this counterregulatory effect of insulin and
corticosterone on adipocyte adaptations.
Note that our finding on Adamts1 expression is
different from a previous study that reported that
dexamethasone-treated mice had a reduced ADAMTS1
abundance in WAT (40). However, another study
demonstrated that cortisol treatment of cultured pre-
adipocytes, obtained from WAT of healthy women who
had undergone hysterectomy, upregulated ADAMTS1
expression (58). These discrepancies may be caused by a
different type, dosage, or duration of GC used among
experiments. Unlike the endogenous GCs cortisol and
corticosterone that can activate both GR and MR,
dexamethasone is a potent GR activator with minimal
mineralocorticoid effects (59), and Adamts1 is reported
to be an MR target gene, at least in cardiomyocytes (60).
Concerning the IPGTT data, an absence in spike of
blood glucose levels in corticosterone-treated female mice
is unlikely caused by a technical error because [U-13C6]-
D-glucose can be detected in the blood of the mice and the
IPGTT was performed simultaneously in all groups of
mice.We speculate that this unique blood glucose pattern
in the corticosterone-treated female mice reflects an ef-
fective b-cell response to secrete insulin for handling the
injected glucose. This is in general confirmed by a recent
study by Gasparini et al. (61) in which it was shown that
only female mice remained insulin-sensitive after 4 weeks
of treatment with ;250 mg corticosterone per day in
drinking water. Although insulin sensitivity was not
assessed directly in our study, note that we found an
increase in fasting insulin levels in both male and fe-
male mice whereas Gasparini et al. (61) found that
corticosterone-treated female mice had an unchanged
insulin concentration. This is likely due to a higher in-
duction of systemic corticosterone levels by the high-
dose corticosterone treatment in our study. Further
studies using hyperinsulinemic–euglycemic clamp, the
gold standardmethod for assessing insulin sensitivity, are
needed to elucidate the effect of chronic high-dose cor-
ticosterone treatment.
Another limitation of our study is the lack of data on
energy expenditure of the animals, as we think that the
increased food consumption can only partially explain
the enhanced fat accumulation and weight gain of the
corticosterone-treated mice. Thus, performing quanti-
tative measurement of physical activity together with
indirect calorimetry is needed in future studies on sex-
dependent corticosterone effects.
A few studies have shown an apparent interaction of
sex steroids with GC activity. For instance, estrogen
depletion in female mice resulted in a GC-driven devel-
opment of hepatic steatosis (45). The consequences of
this on whole-body metabolism was not addressed in the
aforementioned study, but another study revealed that
corticosterone-induced metabolic derangements, such as
BW gain and WAT expansion, were more severe in
ovariectomized than in sham-operated female rats and
were counteracted by estradiol supplementation (52).
Recently, androgens were also reported to modulate GR
activity in liver and adipose tissue of male mice (62).
Although some signs/symptoms such as muscle wasting,
osteoporosis, purple striae, and nephrolithiasis are more
frequent in male patients with Cushing disease, the
prevalence of metabolic derangements in Cushing syn-
drome, such as obesity and glucose abnormalities, does
not differ between men and women (63–65). In contrast,
metabolic derangements upon systemic or topical use
of corticosteroids appeared slightly more frequent in
women than in men (66). Thus, despite the irrefutable
fact that GCs have more metabolically negative effects in
male rodents, which can at least partly be attributed to
differences in sex steroid, the clinical manifestation is
unclear and requires more dedicated studies.
In conclusion, this study illustrates a sex-dependent
insulin resistance caused by continuous treatment with
high-dose corticosterone. Morphological changes upon
metabolic challenges and adipokine secretions from
adipose tissues indicate favorable protective mechanisms
in female mice. This result warrants more careful eval-
uation of sex as a factor in the glucose monitoring
strategy of patients receiving corticosteroid therapy.
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